Quality of life of oropharyngeal cancer patients with respect to treatment strategy and p16-positivity

Laryngoscope

Volumn 123, Issue 1, 2013, Pages 164-170

  Broglie, Martina A ^a   Soltermann, Alex ^b   Haile, Sarah R ^c   Röösli, Christof ^b   Huber, Gerhard F ^b   Schmid, Stephan ^b   Stoeckli, Sandro J ^a  

^a Kantonsspital St Gallen ^*  (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

HPV; intensity modulated radiotherapy; Level of Evidence: 2c; Oropharyngeal squamous cell carcinoma; outcome; p16; quality of life; survival

Indexed keywords

CISPLATIN; PROTEIN P16;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CHEMORADIOTHERAPY; COHORT ANALYSIS; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OROPHARYNX CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; VALIDATION PROCESS; XEROSTOMIA;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; QUALITY OF LIFE; QUESTIONNAIRES; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; SURVIVORS; TREATMENT OUTCOME;

EID: 84871722631     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.23622     Document Type: Article

References (57)

1. Hicks WL, Jr., Kuriakose MA, Loree TR, et al. Surgery versus radiation therapy as single-modality treatment of tonsillar fossa carcinoma: the Roswell Park Cancer Institute experience (1971-1991). Laryngoscope 1998; 108: 1014-9.
2. Perez CA, Patel MM, Chao KS, et al. Carcinoma of the tonsillar fossa: prognostic factors and long-term therapy outcome. Int J Radiat Oncol Biol Phys 1998; 42: 1077-84.
3. Roosli C, Tschudi DC, Studer G, Braun J, Stoeckli SJ,. Outcome of patients after treatment for a squamous cell carcinoma of the oropharynx. Laryngoscope 2009; 119: 534-40.
4. Johansen LV, Grau C, Overgaard J,. Squamous cell carcinoma of the oropharynxa-an analysis of treatment results in 289 consecutive patients. Acta Oncol 2000; 39: 985-94.
5. Lanza L, Rizzi L, Durso D, Occhini A, Benazzo M, Tinelli C,. Integrated treatment in locally advanced carcinoma of the oropharynx. J Surg Oncol 2000; 74: 75-8.
6. Pignon JP, Bourhis J, Domenge C, Designe L,. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355: 949-55.
7. Pignon JP, le Maitre A, Maillard E, Bourhis J,. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4-14.
8. Mendenhall WM, Amdur RJ, Morris CG, Kirwan JM, Li JG,. Intensity-modulated radiotherapy for oropharyngeal squamous cell carcinoma. Laryngoscope 2010; 120: 2218-22.
9. Daly ME, Lieskovsky Y, Pawlicki T, Yau J, Pinto H, Kaplan M, et al. Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma. Head Neck 2007; 29: 211-20.
10. Tribius S, Bergelt C,. Intensity-modulated radiotherapy versus conventional and 3D conformal radiotherapy in patients with head and neck cancer: Is there a worthwhile quality of life gain? Cancer Treat Rev 2011; 37: 511-9.
11. Wan Leung S, Lee TF, Chien CY, Chao PJ, Tsai WL, Fang FM,. Health-related quality of life in 640 head and neck cancer survivors after radiotherapy using EORTC QLQ-C30 and QLQ-H&N35 questionnaires. BMC Cancer 2011; 11: 128.
12. Mork J, Lie AK, Glattre E, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001; 344: 1125-31.
13. Gillison ML,. Human papillomavirus and prognosis of oropharyngeal squamous cell carcinoma: implications for clinical research in head and neck cancers. J Clin Oncol 2006; 24: 5623-5.
14. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
15. Maxwell JH, Kumar B, Feng FY, et al. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res 2010; 16: 1226-35.
16. Braakhuis BJ, Visser O, Leemans CR,. Oral and oropharyngeal cancer in The Netherlands between 1989 and 2006: increasing incidence, but not in young adults. Oral Oncol 2009; 45: e85-9.
17. Conway DI, Stockton DL, Warnakulasuriya KA, Ogden G, Macpherson LM,. Incidence of oral and oropharyngeal cancer in United Kingdom (1990-1999) a-recent trends and regional variation. Oral Oncol 2006; 42: 586-92.
18. Robinson KL, Macfarlane GJ,. Oropharyngeal cancer incidence and mortality in Scotland: are rates still increasing? Oral Oncol 2003; 39: 31-6.
19. Hammarstedt L, Dahlstrand H, Lindquist D, Onelov L, Ryott M, Luo J, et al. The incidence of tonsillar cancer in Sweden is increasing. Acta Otolaryngol 2007; 127: 988-92.
20. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML,. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008; 26: 612-9.
21. Ramqvist T, Dalianis T,. Oropharyngeal cancer epidemic and human papillomavirus. Emerg Infect Dis 2010; 16: 1671-7.
22. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-9.
23. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM,. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 2001; 92: 805-13.
24. Fischer CA, Zlobec I, Green E, Probst S, Storck C, Lugli A, et al. Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality? Int J Cancer 2010; 126: 1256-62.
25. Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006; 24: 5630-6.
26. Haughey BH, Hinni ML, Salassa JR, et al. Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a united states multicenter study. Head Neck 2011; 33: 1683-94
27. Tschudi D, Stoeckli S, Schmid S,. Quality of life after different treatment modalities for carcinoma of the oropharynx. Laryngoscope 2003; 113: 1949-54.
28. Studer G, Furrer K, Davis BJ, et al. Postoperative IMRT in head and neck cancer. Radiat Oncol 2006; 1: 40.
29. Studer G, Huguenin PU, Davis JB, Kunz G, Lutolf UM, Glanzmann C,. IMRT using simultaneously integrated boost (SIB) in head and neck cancer patients. Radiat Oncol 2006; 1: 7.
30. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-52.
31. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005; 27: 843-50.
32. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
33. Bjordal K, de Graeff A, Fayers PM, et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer 2000; 36: 1796-807.
34. Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirusa-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006; 24: 736-47.
35. Reimers N, Kasper HU, Weissenborn SJ, et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 2007; 120: 1731-8.
36. Ritchie JM, Smith EM, Summersgill KF, et al. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 2003; 104: 336-44.
37. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709-20.
38. Chao KS, Wippold FJ, Ozyigit G, Tran BN, Dempsey JF,. Determination and delineation of nodal target volumes for head-and-neck cancer based on patterns of failure in patients receiving definitive and postoperative IMRT. Int J Radiat Oncol Biol Phys 2002; 53: 1174-84.
39. Saarilahti K, Kouri M, Collan J, et al. Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function. Radiother Oncol 2005; 74: 251-8.
40. Kwong DL, Pow EH, Sham JS, et al. Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function. Cancer 2004; 101: 1584-93.
41. Wolden SL, Chen WC, Pfister DG, Kraus DH, Berry SL, Zelefsky MJ,. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 2006; 64: 57-62.
42. van Rij CM, Oughlane-Heemsbergen WD, Ackerstaff AH, Lamers EA, Balm AJ, Rasch CR,. Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life. Radiat Oncol 2008; 3: 41.
43. Yao M, Karnell LH, Funk GF, Lu H, Dornfeld K, Buatti JM,. Health-related quality-of-life outcomes following IMRT versus conventional radiotherapy for oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2007; 69: 1354-60.
44. Mowry SE, Tang C, Sadeghi A, Wang MB,. Standard chemoradiation versus intensity-modulated chemoradiation: a quality of life assessment in oropharyngeal cancer patients. Eur Arch Otorhinolaryngol 2010; 267: 1111-6.
45. Eisbruch A, Schwartz M, Rasch C, et al. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys 2004; 60: 1425-39.
46. Jabbari S, Kim HM, Feng M, et al. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report. Int J Radiat Oncol Biol Phys 2005; 63: 725-31.
47. Levendag PC, Teguh DN, Voet P, et al. Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship. Radiother Oncol 2007; 85: 64-73.
48. Vergeer MR, Doornaert PA, Rietveld DH, Leemans CR, Slotman BJ, Langendijk JA,. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program. Int J Radiat Oncol Biol Phys 2009; 74: 1-8.
49. Peponi E, Glanzmann C, Willi B, Huber G, Studer G,. Dysphagia in head and neck cancer patients following intensity modulated radiotherapy (IMRT). Radiat Oncol 2011; 6: 1.
50. Park YM, Lee JG, Lee WS, Choi EC, Chung SM, Kim SH,. Feasibility of transoral lateral oropharyngectomy using a robotic surgical system for tonsillar cancer. Oral Oncol 2009; 45: e62-6.
51. Bhayani MK, Holsinger FC, Lai SY,. A shifting paradigm for patients with head and neck cancer: transoral robotic surgery (TORS). Oncology (Williston Park) 2010; 24: 1010-5.
52. de Almeida JR, Genden EM,. Robotic surgery for oropharynx cancer: promise, challenges, and future directions. Curr Oncol Rep 2012; 14: 148-57.
53. Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007; 121: 465-72.
54. Sharma A, Mendez E, Yueh B, Lohavanichbutr P, Houck J, Doody DR, et al. Human papillomavirus-positive oral cavity and oropharyngeal cancer patients do not have better quality-of-life trajectories. Otolaryngol Head Neck Surg 2012; 146: 739-45.
55. Bjordal K, Hammerlid E, Ahlner-Elmqvist M, et al. Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol 1999; 17: 1008-19.
56. Hjermstad MJ, Fossa SD, Bjordal K, Kaasa S,. Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. J Clin Oncol 1995; 13: 1249-54.
57. Groenvold M, Klee MC, Sprangers MA, Aaronson NK,. Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. J Clin Epidemiol 1997; 50: 441-50.